Invetx, a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing.
The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC.
The company intends to use the funds to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats.
Led by Juergen Horn, PhD, chief executive officer, Invetx has built an integrated, iscovery, development, and manufacturing platform to create fully species-specific, optimized and half-life extended product candidates. By leveraging validated biotechnologies from human health and optimizing them for application in veterinary medicine, the company can generate differentiated antibodies to treat a wide variety of chronic and serious diseases in animals. Invetx has a broad pipeline of biotherapeutics in various therapeutic areas and expects to advance multiple candidates in development with product approvals anticipated potentially as early as 2025. In addition, the company has established a discovery, development, and commercialization partnership with Boehringer Ingelheim to pursue novel programs in addition to its own product portfolio. Invetx has also expanded its collaborations with AbCellera, Twist Bioscience and Wuxi Biologics.
FinSMEs
10/05/2022